
Genome | Personalized Insulin Pumps Help Patients With Type 1 Diabetes
Personalized Insulin Pumps Help Patients With Type 1 Diabetes
Managing type 1 diabetes is a full-time job, one that bears an unrelenting reminder of the chronic disease through daily injections and pinpricks. But a new clinical trial for a personalized intervention could pave the way to easing the burden for patients with diabetes.
Sponsored by Medtronic, the multicenter nationwide trial is testing a first-of-its-kind, FDA-approved system that uses artificial intelligence to monitor and control participants blood glucose levels. Medtronic first released the MiniMed 670G device used in the trial in 2016 after the FDA decided to fast-track the systems approval.
Now, investigators are enrolling patients for the second cohort of Medtronics four-year clinical trial with the aim of having 1,000 subjects complete the study. The trial divides subjects into three cohorts: those currently using insulin pumps but not blood glucose sensors ; those using a pump and a sensor; and those using neither pumps nor sensors.
Linda Aman, a sub-investigator on the trial, has patients who drive several hours to participate at the Grunberger Diabetes Institute, one of the trial sites in Bloomfield Hills, Michigan, for the promise of a more automated insulin delivery system.
Basically what this pump does, it is supposed to reduce the burden of taking care of [type 1] diabetes, Aman says. Its a very high burden. You have to deliver your insulin somehow either with a pump or with injections or you can inhale it. But you have to do all this in contest with what your blood sugars are doing, so yo
Continue
reading